Molecular and Cellular Biology, September 2001, p. 5935-5945, Vol. 21, No. 17
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.17.5935-5945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Departments of Experimental Oncology1 and Pathology,3 St. Jude Children's Research Hospital, Memphis, Tennessee 38105; Department of Molecular Biology and Hematology, Jichi Medical School, Tochigi 329-04, Japan2; Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada4; and Pediatric Oncology Department, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 021155
Received 10 April 2001/Accepted 23 May 2001
| |
ABSTRACT |
|---|
|
|
|---|
The E2A-HLF fusion gene, formed by the t(17;19)(q22;p13) chromosomal translocation in leukemic pro-B cells, encodes a chimeric transcription factor consisting of the transactivation domain of E2A linked to the bZIP DNA-binding and protein dimerization domain of hepatic leukemia factor (HLF). This oncoprotein blocks apoptosis induced by growth factor deprivation or irradiation, but the mechanism for this effect remains unclear. We therefore performed representational difference analysis (RDA) to identify downstream genetic targets of E2A-HLF, using a murine FL5.12 pro-B cell line that had been stably transfected with E2A-HLF cDNA under the control of a zinc-regulated metallothionein promoter. Two RDA clones, designated RDA1 and RDA3, were differentially upregulated in E2A-HLF-positive cells after zinc induction. The corresponding cDNAs encoded two WD40 repeat-containing proteins, Grg2 and Grg6. Both are related to the Drosophila protein Groucho, a transcriptional corepressor that lacks DNA-binding activity on its own but can act in concert with other proteins to regulate embryologic development of the fly. Expression of both Grg2 and Grg6 was upregulated 10- to 50-fold by E2A-HLF. Immunoblot analysis detected increased amounts of two additional Groucho-related proteins, Grg1 and Grg4, in cells expressing E2A-HLF. A mutant E2A-HLF protein with a disabled DNA-binding region also mediated pro-B cell survival and activated Groucho-related genes. Among the transcription factors known to interact with Groucho-related protein, only RUNX1 was appreciably downregulated by E2A-HLF. Our results identify a highly conserved family of transcriptional corepressors that are activated by E2A-HLF, and they suggest that downregulation of RUNX1 may contribute to E2A-HLF-mediated leukemogenesis.
| |
INTRODUCTION |
|---|
|
|
|---|
Transcription factor genes that regulate blood cell development are the most frequent targets of chromosomal translocations in the acute leukemias (31, 45). The chimeric or dysregulated proteins resulting from these rearrangements contribute to leukemogenesis, most likely by aberrantly controlling the expression of downstream genes critical for the growth, differentiation, or survival of hematopoietic progenitors. The E2A gene, a member of the basic helix-loop-helix (bHLH) family, encodes two alternatively spliced bHLH transcription factors, E12 and E47, which act synergistically to promote B-lymphocyte maturation (2, 3, 53, 54). E2A is targeted by two translocations in the human leukemias. The t(1;19) generates the E2A-PBX1 chimera, consisting of the AD1 and AD2 transactivation domains of E2A fused to the homeobox DNA-binding domain of PBX1 (26, 38), while the t(17;19) links the same two domains of E2A with the bZIP DNA-binding and protein dimerization domain of hepatic leukemia factor (HLF) (17, 21).
To elucidate the mechanism by which E2A-HLF subverts normal developmental pathways, we programmed t(17;19)-positive leukemia cells to express a dominant-negative suppressor of the oncoprotein (20). When E2A-HLF function was blocked, the transformed cells died by apoptosis, suggesting that the oncoprotein affects cell survival rather than cell growth. This interpretation was substantiated by additional experiments in which E2A-HLF reversed both apoptosis by interleukin-3 (IL-3) deprivation and p53 activation in murine pro-B lymphocytes (20). To determine the structural motifs that contribute to the antiapoptotic activity of E2A-HLF, we constructed a panel of E2A-HLF mutants and programmed their expression in IL-3-dependent murine pro-B cells, using a zinc-inducible vector (22). Neither the E12 nor the E47 product of the E2A gene nor the wild-type HLF protein was able to protect the cells from apoptosis induced by IL-3 deprivation. Surprisingly, different combinations of disabling mutations within the HLF bZIP domain had little effect on the antiapoptotic property of the chimeric protein, so long as the amino-terminal portion of E2A was left intact. In the context of an intact HLF bZIP domain, the AD1 but not the AD2 transactivation domain was required for antiapoptotic activity. However, in constructs with a defective bZIP domain, either transactivating region (AD1 or AD2) could promote cell survival after growth factor deprivation. Thus, the block of apoptosis imposed by E2A-HLF in pro-B lymphocytes depends critically on the transactivating regions of E2A. Our findings suggest dual mechanisms of E2A-HLF action, one in which the AD1 and bZIP domains act cooperatively to block apoptosis and another in which protein-protein interactions with the amino-terminal region of E2A act to block the expression of genes that normally control the apoptotic machinery of pro-B cells (22).
In this study, we used representational difference analysis (RDA) to identify genes that are differentially regulated in response to enforced expression of E2A-HLF in murine FL5.12 pro-B cells. Two such genes, designated Grg2 and Grg6, are related to the Drosophila gene Groucho, which encodes a protein that acts as a transcriptional corepressor, interacting with specific subsets of DNA-binding transcription factors. Immunoblot analysis identified two other Groucho-related proteins, Grg1 and Grg4, whose genes were coordinately upregulated with Grg2 and Grg6. Among the transcription factors known to interact with the Groucho family of corepressors, only RUNX1 was specifically downregulated by E2A-HLF. Thus, Groucho-related proteins and the RUNX1 transcription factor are likely candidates to participate as downstream effectors in E2A-HLF-mediated oncogenesis.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture and cell survival assay. IL-3-dependent FL5.12 murine pro-B cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum and 10% WEHI-3B-conditioned medium (as a source of IL-3). The cell number was maintained below 106/ml to avoid IL-3-independent growth. Cell lines expressing E2A-HLF or E2A-HLF mutants from the pMT-CB6+ eukaryotic expression vector (a gift from F. Rauscher III, Wistar Institute, Philadelphia, Pa.) have been described previously (22).
For cell survival assays, protein expression was induced by treating cells with 100 µM ZnSO4 for 16 h prior to growth factor deprivation. IL-3 was removed by repeated centrifugation in fresh medium lacking the cytokine, and the cells were adjusted to 5 × 105 per ml on day 0 and cultured without IL-3. Viable cell counts were determined in triplicate by trypan blue dye exclusion.RDA. RDA was performed according to the method of Hubank and Schatz (16) with additional modifications. Poly(A)+ RNAs were isolated from FL5.12 cells harboring the E2A-HLF construct and grown in the presence or absence of 100 µM ZnSO4 by use of the FastTrack 2.0 mRNA isolation system (Invitrogen). Double-stranded cDNAs were synthesized with the Superscript cDNA synthesis kit (GIBCO-BRL) according to the manufacturer's protocol. Double-stranded cDNA (2 µg) isolated from both cells grown in the presence of zinc and cells deprived of zinc was digested with DpnII, ligated with adapter, and amplified by PCR (16, 28). RDA fragments were isolated after three cycles of subtractive hybridization and selective PCR amplification with different adapters. The third difference products were digested with DpnII and cloned into the BamHI site of the pBluescript phagemid (Stratagene). Double-stranded plasmid DNA was prepared and sequenced, and findings were compared with the GenBank database by use of the BLAST program.
Screening of cDNA library. The full-length cDNAs of RDA1 and RDA3 (designated Grg2 and Grg6, respectively) were isolated by screening a cDNA library that was constructed with mRNA isolated from E2A-HLF-expressing Baf-3 mouse pro-B cells. The pBK-CMV phagemid was purified from positive clones by in vivo excision from the lambda ZAP II vector, using ExAssist helper phage (Stratagene). The GenBank accession numbers for Grg2 and Grg6 are AF145958 and AF145957, respectively.
Northern blot analysis. Two micrograms of mRNA or 10 µg of total RNA was subjected to denaturing agarose electrophoresis in 1 M formaldehyde and transferred to a nylon membrane (Stratagene). The blots were then hybridized with cDNA probes labeled with [32P]dCTP. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control in quantifying the levels of mRNA expression. After hybridization, the blots were analyzed with a PhosphorImager (Molecular Dynamics).
Protein expression. Expression plasmids for human TLE1 and TLE2 and mouse Grg6 were generated by subcloning the full-length coding sequences of these cDNA inserts into the pMT-CB6+ eukaryotic expression vector, which provides inducible gene expression under control of the sheep metallothionein promoter. This vector also contains the neomycin resistance gene (neo) driven by the simian virus 40 (SV40) promoter. A Kozak sequence was placed in front of ATG in these cDNA inserts.
Antibodies and Western blot analysis. Rabbit polyclonal antibodies were raised against the N terminus (3 to 68 amino acids; Bio-80) and middle portion (186 to 272 amino acids; Bio-81) of Grg6. A rabbit polyclonal antibody against HLF was made as previously described (23). The pan-transducin-like enhancer-of-split (TLE) monoclonal antibody C597.4A and rabbit polyclonal antibodies against amino acids unique to each human TLE protein (TLE1, TLE2, TLE3, and TLE4) were prepared as indicated previously (18, 50). A rabbit polyclonal antibody against Runx1 (AML1/RHD; Ab-2) was obtained from Calbiochem, and a goat polyclonal antibody against actin (C-11) was obtained from Santa Cruz Biotechnology.
Cells were lysed in NP-40 lysis buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris [pH 8.0]), and total cellular proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrotransfer onto nitrocellulose membranes, the blots were stained either with specific TLE antibodies (1:2,000 dilution) and anti-Grg6 (1:400 dilution) followed by horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) or with a pan-TLE antibody (1:400 dilution) followed by an anti-rat IgG. The bands were visualized by enhanced chemiluminescence according to the manufacturer's instructions (Amersham).RNase protection analysis. An RNase protection assay (RPA) was performed with the In Vitro Transcription/Ribonuclease Protection Assay Kit (PharMingen) according to the manufacturer's instructions. In brief, total RNA (20 µg) isolated from FL5.12 cells was hybridized with [32P]UTP-labeled antisense RNA probes (~107 cpm per reaction mixture) at 56°C for 16 h, then heated at 90°C for 3 min, and digested with RNase. The templates from Grg6 and Runx1 for RPA were prepared by inserting a 199-bp PCR fragment of Grg6 cDNA (bp 152 to 350) and a 310-bp Runx1 fragment (bp 822 to 1131) into the pcDNA3 vector in antisense orientations relative to the T7 polymerase transcription origin. The 95-bp mouse Gapdh cDNA fragment (PharMingen) was used as an internal control.
RT-PCR.
Total RNA was extracted from cells using the Trizol
reagent (LTI, Inc.), by following the manufacturer's directions.
Reverse transcription was performed on 2 µg of total RNA. RNA was
resuspended in a final volume of 11 µl with 50 ng of random hexamer
(Pharmacia Biotech), incubated at 80°C for 5 min, and cooled on ice.
Reverse transcription was performed using 200 U of SuperScriptII
reverse transcriptase (GIBCO-BRL) in the manufacturer's buffer in the presence of 0.5 mM deoxynucleoside triphosphates (dNTP)-1.0 mM dithiothreitol in a final volume of 20 µl, which was incubated at
42°C for 1 h. After the reaction, each sample was added to 1 µl of RNase H (GIBCO-BRL) and incubated at 37°C for 20 min. For the
negative control, the reaction was also performed on each sample
without reverse transcriptase (RT). cDNA samples were stored at
20°C. PCRs were performed using a DNA Thermal cycler
(Perkin-Elmer). PCR mixtures contained 1 µl of cDNA, 1× reaction
buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 10 pmol of each primer,
and 2.5 U of Taq polymerase (Perkin-Elmer) in a total volume
of 50 µl. The thermocycling parameters and the sequences of the
specific primers for PCR are as follows: for TLE1, 30 cycles at 94°C
for 30 s, 50°C for 30 s, and 72°C for 1 min with sense
primer 5'-AATCGCCAAGAGATTGAATA-3' and antisense primer
5'-GTGCCTCTTAGACTGTCGG-3'; for TLE2, 40 cycles at 94°C for
30 s, 52°C for 30 s, and 72°C for 1 min with sense primer 5'-AGCAGAGAGCAGATGAGAAG-3' and antisense primer
5'-GAGAGGTCTCCGTTGAGAGT-3'; for TLE3, 30 cycles at 94°C
for 30 s, 52°C for 30 s, and 72°C for 1 min with sense
primer 5'-TACGACAGTGATGGAGACAA-3' and antisense primer
5'-CATTATACCTATCGGGTCCA-3'; for TLE4, 30 cycles at 94°C for 30 s, 52°C for 30 s, and 72°C for 1 min with sense primer 5'-GTTTGTAAGCACTGGAAAGG-3' and antisense primer
5'-AAAAAGGATGACAGAGCAAA-3'; for AML-1, 40 cycles at 94°C
for 30 s, 54°C for 30 s, and 72°C for 1 min with sense
primer 5'-AGACATCGGCAGAAACTAGA-3' and antisense primer
5'-CCAGGTATTGGTAGGACTGA-3'; for c-ABL, 30 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min with sense primer 5'-GTATCATCTGACTTTGAGCC-3' and antisense primer
5'-GTACAGGAGTGTTTCTCCA-3'. Amplification of c-ABL mRNA was
performed to assess the quality of RNA extraction. These primer sets
amplify a 342-bp product of TLE1, a 501-bp product of TLE2, a 501-bp
product of TLE3, a 501-bp product of TLE4, a 253-bp product of AML-1,
and a 288-bp product of c-ABL. Ten microliters of the PCR products was
electrophoresed in a 2.0% agarose gel and transferred onto a nylon
membrane (NEN Life Science) with 0.4 N NaOH. Membranes were hybridized
with an internal probe end labeled with 32P using
polynucleotide kinase, and autoradiography was performed. The sequences
of the internal probes were as follows: for TLE1, 5'-ACCCTCCCTGACCTGTCTCG-3'; for TLE2,
5'-CTCATTGTGGCCCTTATGTA-3'; for TLE3,
5'-GAGAAATTGACTGCTCGAGT-3'; for TLE4,
5'-TAACTAAAGGTGAAAAGCTCC-3'; for AML-1,
5'-AACCCTCAGCCTCAGCGTCA-3'; and for c-ABL,
5'-TAACTAAAGGTGAAAAGCTCC-3'.
Nucleotide sequence accession numbers. The GenBank accession numbers for Grg2 and Grg6 are AF145958 and AF145957, respectively.
| |
RESULTS |
|---|
|
|
|---|
Identification of genes that are upregulated by E2A-HLF. Overexpression of E2A-HLF protects pro-B cells from death induced by growth factor deprivation or irradiation (20). We have previously shown that IL-3-dependent murine pro-B cells (FL5.12 or BAF-3 cell lines) can survive in the absence of the cytokine when E2A-HLF expression is controlled by a metallothionein-regulated vector (20, 22). To identify downstream genes targeted by the E2A-HLF oncoprotein, we performed RDA on the mRNAs of FL5.12 pro-B cells shortly after removal of IL-3 from the culture medium. The so-called "tester" E2A-HLF+ mRNAs were extracted from cells that had been incubated in the presence of both IL-3 and 100 µM ZnSO4 for 18 h to induce E2A-HLF expression and maintained in the same concentration of zinc but deprived of IL-3 for an additional 12 h. The control or "driver" mRNAs were extracted from the same cell clone after identical treatment, except that E2A-HLF expression was not induced by the addition of zinc to the medium.
After three rounds of sequential hybridization and PCR amplification according to the RDA protocol of Hubank and Schatz (16), we isolated three clones (RDA1, RDA3, and RDA9) that were differentially expressed in E2A-HLF-positive cells compared with controls. RDA1 contains a 239-bp cDNA fragment that hybridized with an mRNA of approximately 3 kb (Fig. 1). This transcript was expressed at high levels in FL5.12 cells induced to express E2A-HLF, whether or not IL-3 was present in the culture medium (Fig. 1A, lanes 6 and 8). The same cells did not express detectable levels of the RDA1 mRNA in the absence of zinc (Fig. 1A, lanes 5 and 7). The 300-bp RDA3 cDNA fragment hybridized with an mRNA of approximately 2 kb in E2A-HLF-transfected FL5.12 cells (Fig. 1). RDA3 mRNA was also undetectable in control FL5.12 cells but was strikingly upregulated after addition of zinc in the presence or absence of IL-3 (Fig. 1A, lanes 6 and 8). A 454-bp RDA9 cDNA fragment also hybridized with a 2-kb transcript (data not shown). Subsequent analysis of the complete sequence of the cDNA clones identified by these probes showed that both RDA3 and RDA9 are represented in the 3' and middle portions of the same mRNA.
|
AD1
mutant, which lacks the entire AD1 transactivation domain but possesses
an intact HLF DNA-binding domain, failed to induce expression of either
RDA1 or RDA3 (lanes 9 and 10). By contrast, a mutant defective in
DNA-binding activity [E2A-HLF (BX)], as a result of substitutions for
six critical amino acids in the HLF basic region (22),
stimulated RDA1 and RDA3 expression as efficiently as the wild-type
protein (Fig. 1A, lanes 11 and 12). Thus, activation of these candidate
genes requires an intact AD1 domain but not sequence-specific DNA
binding through the bZIP domain of HLF, mirroring the ability of these
mutants to prolong cell survival in the absence of cytokine.
The timing of RDA3 mRNA accumulation relative to the induction of
E2A-HLF expression is shown in Fig. 2.
Low baseline levels of E2A-HLF maintained by the metallothionein vector
increased markedly within 2 h after zinc addition, while
expression of RDA3 mRNA was first detected 8 h after incubation of
the cells with zinc, reaching maximal levels within 12 h. A
similar kinetic profile was observed for RDA1 mRNA (data not shown).
|
Both RDA1 and RDA3 are homologous to the Drosophila
gene Groucho.
DNA sequence analysis revealed that RDA1
is closely related to the human gene TLE2, one of several
mammalian genes related to the Drosophila gene
Groucho (27, 29, 36, 50). Although murine
homologues have been identified for most of the TLE genes, none has been found for TLE2 (29). To clone the
full-length coding sequence of RDA1, we isolated multiple cDNA clones
from a library prepared from a Baf-3 murine pro-B cell line programmed to express E2A-HLF. The longest cDNA consisted of 2,749 bp, including one long open reading frame that encoded a 767-amino-acid protein (GenBank accession number AF145958) which did not correspond to any of
the previously identified murine Grg proteins (29). Because of the high degree of amino acid sequence identity (87%) between the murine protein and human TLE2, we concluded that RDA1 represents the murine homologue, Grg2 (Fig.
3). The predicted Grg2 protein contains a
23-amino-acid insertion near its amino terminus that is not shared with
TLE2, but otherwise these proteins are very highly conserved (90%
amino acid identity).
|
|
Upregulation of a family of Groucho-related proteins in response to
E2A-HLF expression.
Identification by RDA of two Grg
genes that are upregulated by E2A-HLF suggested that increased amounts
of other Grg family members might be detectable after enforced
expression of the oncoprotein. As shown in Fig.
5, E2A-HLF expression was apparent within
6 h after addition of zinc to FL5.12 cells bearing the fusion
construct and reached maximal levels by 24 h. To analyze the
pattern of Grg protein expression, we first used a monoclonal antibody
(C597.4A) (50) that recognizes all the human TLE proteins
and then used antibodies specific for each of these proteins. The Grg
proteins recognized by the pan-TLE antibody were expressed at low
levels in murine FL5.12 cells before induction of E2A-HLF expression, with increased expression apparent 12 h after zinc addition (Fig. 5). Maximal expression of TLE proteins occurred after 24 h and was
maintained through 48 h. The Grg1, Grg2, and Grg4 proteins showed
similar expression patterns (Fig. 5), while Grg3 was not detected at
any time (data not shown).
|
Lack of antiapoptotic activity by Grg proteins.
Since E2A-HLF
protects IL-3-dependent murine pro-B cells from apoptosis due to IL-3
deprivation (20, 22), we asked whether any of the the
Groucho-related proteins TLE1, TLE2, and Grg6 could replace this
function in the absence of the oncoprotein. We therefore transfected
FL5.12 cells with a zinc-regulated vector encoding either the murine
Grg6 protein or human TLE1 or TLE2. Independent clones isolated by G418
selection expressed each of the proteins in the presence of 100 µM
ZnSO4 at levels approximately 10-fold higher than the
background levels in medium lacking the metal (Fig.
6A). As shown in Fig. 6B, FL5.12 cells
expressing E2A-HLF survived with little loss of viability, while those
expressing TLE1, TLE2, or Grg6 rapidly underwent apoptosis after
removal of IL-3 from the growth medium. These observations indicate
that enforced expression of the individual Groucho-related proteins cannot replace the antiapoptotic function of E2A-HLF.
|
Analysis of RUNX1 (PEBP2
b) and other transcription factors known
to interact with Grg proteins.
The Groucho protein and its
mammalian homologues lack DNA-binding domains and act as
transcriptional corepressors, that is, they interact with DNA-binding
transcription factors to downregulate gene expression (11,
41). Thus, we reasoned that E2A-HLF might block programmed cell
death by regulating both a subset of the Grg proteins and one or more
of the transcription factors with which these proteins interact. This
would account for the failure of individual Grg proteins to block
apoptosis in cells deprived of IL-3. In Drosophila
melanogaster, Groucho interacts with discrete families of
transcription factors, including Hairy, Runt, Engrailed, Dorsal, and
Tcf, and acts as a corepressor with widespread roles in development
(1, 5, 9, 25, 51).
AD1 and BX). The AD1 domain of
the E2A portion was required for this inhibitory effect, as deletion of
this region completely abolished the downregulation of RUNX1 by
E2A-HLF. By contrast, the E2A-HLF(BX) mutant was as potent as wild-type
E2A-HLF in mediating RUNX1 downregulation, indicating that
sequence-specific DNA binding by E2A-HLF is not required for this
effect of the protein, as was previously observed for its antiapoptotic
activity and its ability to upregulate the expression of
Groucho-related genes. Enforced expression of E12 or
wild-type HLF had little discernible effect on RUNX1 mRNA
levels, whereas TEF, a transcription factor that recognizes the same
DNA-binding motif as HLF, markedly downregulated RUNX1 mRNA
levels.
|
|
|
Runx1 expression levels are unaffected by enforced expression of
Groucho-related proteins.
The Runx1 protein contains a WRPY motif
at its carboxyl terminus, and Groucho-related proteins are known to
interact through this motif to convert Runx1 from a transcriptional
activator into a repressor (1, 19, 30). Furthermore, the
Runx1 promoter contains its own core DNA-binding motif, and
published evidence suggests that Runx1 may in part regulate
its own expression (13). Thus, we tested whether
overexpression of Groucho-related proteins alone in FL5.12 cells was
sufficient to downregulate RUNX1 gene expression through an
autoregulatory mechanism. The expression levels of Runx1 were tested by
RPA in FL5.12 cells expressing zinc-inducible Grg proteins (see Fig. 6)
and were unchanged in TLE1-, TLE2- and Grg6-transfected FL5.12 cells
after addition of the metal (Fig. 10,
lanes 6 to 11). Similarly, equal levels of the 310-bp protected band of
Runx1 were detected in control pMT vector-transfected cells
in the presence or absence of zinc (Fig. 10, lanes 2 and 3). By
contrast, the Runx1 mRNA level in E2A-HLF-transfected cells
was significantly decreased by the oncoprotein after addition of zinc
(Fig. 10, lanes 4 and 5). As expected, the 199-bp protected
Grg6 band was detected only in E2A-HLF-positive and
Grg6-positive cells, not in TLE1- and TLE2-transfected cells. These
results suggested that expression of TLE1, TLE2, and Grg6 alone could
not substitute for E2A-HLF in mediating the repression of Runx1.
|
Expression of Groucho-related genes in early B lineage
leukemias.
To assess the expression of the human homologues of
Groucho in early B-lineage leukemia cells, we performed
RT-PCR analysis of leukemic cell lines with and without the t(17;19)
translocation. As shown in Fig. 11, all
t(17;19)-positive cell lines, including UOC-B1, YCUB-2, and HAL-01,
expressed mRNAs encoding TLE1, TLE2, and TLE4 (lanes 1 to 3). Moreover,
TLE3 was expressed in HAL-01 cells but not in the other two
t(17;19)-positive cell lines. Examples of RNAs from five other leukemia
cell lines lacking t(17;19) are also shown in Fig. 11, including the
Nalm6, REH, and 697 early B-lineage, Jurkat T-cell, and U937 monocytic
cell lines. Like t(17;19)-positive cell lines, all these
t(17;19)-negative cell lines except U937 expressed TLE1, TLE2, and
TLE4, but only Jurkat and REH cells expressed TLE3. By contrast,
expression level of RUNX1 was very low in all of the cell lines and
could not be detected under the same PCR conditions used for the
analysis of the TLE genes (data not shown). Thus, our analysis suggests
that Groucho-related genes are expressed in human leukemias
including those with the t(17;19) translocation and that the expression
level of Runx1 is very low.
|
| |
DISCUSSION |
|---|
|
|
|---|
Many chimeric and dysregulated transcription factors have been identified in association with chromosomal translocations in the human acute leukemias (31). In recent years, major efforts have been made to link these genes and their mutated counterparts in multistep pathways that regulate programs of gene expression during development. Recent studies revealed that E2A-HLF protects IL-3-dependent pro-B cells from apoptosis induced by growth factor deprivation or irradiation, suggesting that this chimeric transcription factor may cause leukemia by interfering with apoptotic responses in normal cells. In this study, we used RDA to identify E2A-HLF-regulated genes, including two murine homologues of the gene encoding the Groucho developmental regulator in Drosophila, designated Grg2 and Grg6. Analysis of other members of the Grg family revealed that Grg1 and Grg4 were also activated by E2A-HLF. Among transcription factors that have been shown to interact with Groucho-related proteins, we found that RUNX1, a frequent target of chromosomal abnormalities and inactivating point mutations in human leukemia (8, 40, 49), was suppressed by E2A-HLF.
The Drosophila Groucho protein is a widely expressed nuclear protein that has critical roles in many development processes (11, 41, 42). Groucho lacks a DNA-binding domain but contains a conserved C-terminal WD repeat domain that is present in a large number of proteins performing various cellular functions, including transcriptional regulation and signal transduction, and is believed to mediate protein-protein interactions (37, 48). In Drosophila, Groucho acts as a transcriptional corepressor to modulate gene expression through its associations with numerous transcription factors including Hairy, Runt, engrailed, Tcf, Dorsal, and Hkb (1, 5, 9, 14, 25, 51). These sequence-specific transcription factors recruit Groucho to the target gene promoters through different interaction domains. Hairy and Runt proteins interact with Groucho through their C-terminal WRPW or WRPY motifs (1, 12), whereas Dorsal binds Groucho through its Rel homology domain (52) and Tcf interacts with Groucho through an HMG domain that also mediates its interaction with CBP (46). Once targeted to the promoter region in a heterocomplex with one of these transcription factors, Groucho can actively repress both basal and activated transcription (11, 25). The mechanism underlying Groucho-mediated repression appears to be linked to the direct recruitment of histone deacetylase (HDAC) with its associated chromatin-modifying activities. More recently, it has been shown that the HDAC Rpd3 activity is required for Groucho-mediated transcriptional repression during Drosophila development (6). In addition, NK-3, a homeodomain transcription factor, has recently been shown to recruit both the Groucho corepressor and an HDAC complex with HIPK2 to repress gene expression (7). Many mammalian Groucho homologues have been identified in humans (TLE genes) and mice (Grg) (27, 29, 32, 36, 50). These mammalian Groucho family members are highly conserved and have similar functions in transcriptional repression (11, 15, 37). In mammalian cells, Groucho proteins have been shown to be involved in both Notch and Wnt signaling pathways through interaction with Hes and Tcf transcription factors, respectively (5, 10, 30, 35, 43, 44).
Activation of several Grg family members by E2A-HLF suggests the
possibility that they may contribute to an E2A-HLF-mediated antiapoptotic pathway of leukemogenesis. In FL5.12 cells transfected with Grg genes, however, we did not see protection from cell
death after growth factor deprivation, indicating that increased
expression levels of Groucho proteins alone were insufficient to block
apoptosis. Since Groucho acts as a corepressor in transcriptional
regulation, we considered the possibility that specific DNA-binding
transcription factors might be required to prevent apoptosis. In
Drosophila, a number of transcription factors are known to
interact with Groucho and control cell fate determination. Recently, it
has been shown that Re1/NF-
B, a mammalian homologue of Dorsal, is
involved in suppressing p53-independent apoptosis induced by Ras
(34) and that inhibition of NF-
B activity induces
apoptosis (4). Jehn et al. have reported that Notch-1
protects T-cell receptor (TCR)-induced apoptosis (24),
suggesting that Hes, the downstream genes activated by Notch signaling,
may be involved in cell survival. Among these Groucho-interacting
transcription factors (including RUNX1, NF-
B, Hes-1, Tcf-1, Lef-1,
and En-1), however, only the expression levels of RUNX1 were affected
in E2A-HLF-expressing cells.
RUNX1 is affected by several of the most frequent chromosomal
abnormalities associated with human leukemia (39, 40, 47). Since this transcription factor controls many genes that are important in hematopoiesis (40), downregulation of RUNX1 may play an
important role in E2A-HLF-mediated leukemogenesis. TLE1 has been
demonstrated to inhibit RUNX1-induced transactivation by interacting
with this protein (19, 30), effectively converting RUNX1
from an activator to a repressor of gene expression. For example, in
conjunction with TLE1, RUNX1 negatively regulates the activity of
TCR
and TCR
enhancers (30). Binding of TLE1 to RUNX1
was also found to suppress activities of the macrophage
colony-stimulating factor and neutrophil elastase promoters
(19). This binding is necessary for RUNX1-mediated
repression, because RUNX1-induced transactivation was recovered when
the interaction was abolished by deletion of the C terminus of RUNX1.
Thus, downregulation of RUNX1 by E2A-HLF may block Groucho-mediated
repression through AML pathways and provides another mechanism through
which inhibition of RUNX1 contributes to leukemia in humans
(8).
Upregulation of Grg proteins and downregulation of RUNX1 in response to E2A-HLF emphasize the fact that this chimeric oncoprotein is able to regulate gene expression both positively and negatively, either directly or through intermediate pathways of transcriptional control. Recently, we have shown that E2A-HLF-mediated prevention of apoptosis in IL-3-dependent pro-B cells depends critically on protein-protein interactions mediated by the intact transactivation domains of E2A (23). Data presented here support this mechanism, showing that E2A-HLF activation of Groucho-related genes depends on the AD1 transactivation domain of E2A but not on the DNA-binding activity of HLF. We have detected a significant increase in Grg6 promoter activity in E2A-HLF-transfected cells (data not shown). Identification of E2A-HLF-responsive elements in the promoter regions of Grg genes will be required to implicate a direct effect of E2A-HLF in the activation of Grg genes.
Chimeric and dysregulated transcription factors, created by chromosomal translocation in the acute leukemias, act in concert with other mutations in multistep pathways leading to leukemogenesis. Identification of a family of Groucho-related genes and RUNX1 as potential downstream targets of the E2A-HLF oncoprotein provide direct evidence for its ability to profoundly alter the transcriptional status of early B-lineage cells. Although the relevance of Grg proteins to leukemogenesis has not been conclusively established, RUNX1 is the gene most commonly disrupted by chromosomal abnormalities (8) and inactivated by point mutation in human leukemia (49). The functional analysis of downstream genes in E2A-HLF transcriptional programs may therefore provide useful insights into E2A-HLF-mediated survival advantages as well as leukemogenesis. In addition, identification of the transcription factor(s) involved in regulation of Grg and/or RUNX1 expression should be valuable for elucidating the mechanism by which the Groucho corepressors are activated by E2A-HLF.
| |
ACKNOWLEDGMENTS |
|---|
We thank Jing Wu and Bart Jones for technical assistance. We also thank Karen M. Rakestraw and Clayton W. Naeve of the Center for Biotechnology for DNA sequence analysis.
This work was supported in part by NIH grants CA59571 and CA21765 (Cancer Center CORE Grant), and The American Lebanese Syrian Associated Charities (ALSAC), St. Jude Children's Research Hospital.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Pediatric Oncology Department, Mayer-630, Dana-Farber Cancer Institute, Boston, MA 02115. Phone: (617) 632-5826. Fax: (617) 632-6989. E-mail: thomas_look{at}dfci.harvard.edu.
Present address: Department of Pediatrics, Yamanashi Medical
University, Tamaho, Yamanashi 409-38, Japan.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aronson, B. D., A. L. Fisher, K. Blechman, M. Caudy, and J. P. Gergen. 1997. Groucho-dependent and -independent repression activities of runt domain proteins. Mol. Cell. Biol. 17:5581-5587[Abstract]. |
| 2. | Bain, G., E. C. Robanus-Maandag, D. J. Izon, D. Amsen, A. M. Kruisbeek, B. C. Weintraub, I. Krop, M. S. Schlissel, A. J. Feeney, M. van Roon, M. van der Valk, H. P. J. te Riele, A. Berns, and C. Murre. 1994. E2A proteins are required for proper B-cell development and initiation of immunoglobulin gene rearrangements. Cell 79:885-892[CrossRef][Medline]. |
| 3. | Bain, G., E. C. Robanus Maandag, H. P. te Riele, A. J. Feeney, A. Sheehy, M. Schlissel, S. A. Shinton, R. R. Hardy, and C. Murre. 1997. Both E12 and E47 allow commitment to the B cell lineage. Immunity 6:145-154[CrossRef][Medline]. |
| 4. |
Bellas, R. E.,
M. J. FitzGerald,
N. Fausto, and G. E. Sonenshein.
1997.
Inhibition of NF- B activity induces apoptosis in murine hepatocytes.
Am. J. Pathol.
151:891-896[Abstract].
|
| 5. | Cavallo, R. A., R. T. Cox, M. M. Moline, J. Roose, G. A. Polevov, H. Clevers, M. Pfeifer, and A. Bejsovec. 1998. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395:604-608[CrossRef][Medline]. |
| 6. |
Chen, G.,
J. Fernandez,
S. Mische, and A. J. Courey.
1999.
A functional interaction between the histone deacetylase Rpd3 and the corepressor Groucho in Drosophila development.
Genes Dev.
13:2218-2230 |
| 7. |
Choi, C. Y.,
Y. H. Kim,
H. J. Kwon, and Y. Kim.
1999.
The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription.
J. Biol. Chem.
274:33194-33197 |
| 8. | Downing, J. R. 1999. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br. J. Haematol. 106:296-308[CrossRef][Medline]. |
| 9. |
Dubnicoff, T.,
S. A. Valentine,
G. Chen,
T. Shi,
J. A. Lengyel,
Z. Paroush, and A. J. Courey.
1997.
Conversion of Dorsal from an activator to a repressor by the global corepressor Groucho.
Genes Dev.
11:2952-2957 |
| 10. | Eastman, Q., and R. Grosschedl. 1999. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell Biol. 11:233-240[CrossRef][Medline]. |
| 11. |
Fisher, A. L., and M. Caudy.
1998.
Groucho proteins: transcriptional corepressors for specific subsets of DNA-binding transcription factors in vertebrates and invertebrates.
Genes Dev.
12:1931-1940 |
| 12. | Fisher, A. L., S. Ohsako, and M. Caudy. 1996. The WRPW motif of the Hairy-related basic helix-loop-helix repressor proteins acts as a 4-amino-acid transcription repression and protein-protein interaction domain. Mol. Cell. Biol. 16:2670-2677[Abstract]. |
| 13. |
Ghozi, M. C.,
Y. Bernstein,
V. Negreanu,
D. Levanon, and Y. Groner.
1996.
Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions.
Proc. Natl. Acad. Sci. USA
93:1935-1940 |
| 14. | Goldstein, R. E., G. Jimenez, O. Cook, D. Gur, and Z. Paroush. 1999. Huckebein repressor activity in Drosophila terminal patterning is mediated by Groucho. Development 126:3747-3755[Abstract]. |
| 15. | Grbavec, D., R. Lo, Y. Liu, and S. Stifani. 1998. Transducin-like Enhancer of split 2, a mammalian homologue of Drosophila Groucho, acts as a transcriptional repressor, interacts with Hairy/Enhancer of split proteins, and is expressed during neuronal development. Eur. J. Biochem. 258:339-349[Medline]. |
| 16. |
Hubank, M., and D. G. Schatz.
1994.
Identifying differences in mRNA expression by representational difference analysis of cDNA.
Nucleic Acids Res.
22:5640-5648 |
| 17. |
Hunger, S. P.,
K. Ohyashiki,
K. Toyama, and M. L. Cleary.
1992.
Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17; 19) acute lymphoblastic leukemia.
Genes Dev.
6:1608-1620 |
| 18. | Husain, J., R. Lo, D. Grbavec, and S. Stifani. 1996. Affinity for the nuclear compartment and expression during cell differentiation implicate phosphorylated Groucho/TLE1 forms of higher molecular mass in nuclear functions. Biochem. J. 317:523-531. |
| 19. | Imai, Y., M. Kurokawa, K. Tanaka, A. D. Friedman, S. Ogawa, K. Mitani, Y. Yazaki, and H. Hirai. 1998. TLE, the human homolog of Groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem. Biophys. Res. Commun. 252:582-589[CrossRef][Medline]. |
| 20. | Inaba, T., T. Inukai, T. Yoshihara, H. Seyschab, R. A. Ashmun, C. E. Canman, S. J. Laken, M. B. Kastan, and A. T. Look. 1996. Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature 382:541-544[CrossRef][Medline]. |
| 21. |
Inaba, T.,
W. M. Roberts,
L. H. Shapiro,
K. W. Jolly,
S. C. Raimondi,
S. D. Smith, and A. T. Look.
1992.
Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia.
Science
257:531-534 |
| 22. |
Inukai, T.,
T. Inaba,
S. Ikushima, and A. T. Look.
1998.
The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF.
Mol. Cell. Biol.
18:6035-6043 |
| 23. | Inukai, T., T. Inaba, T. Yoshihara, and A. T. Look. 1997. Cell transformation mediated by homodimeric E2A-HLF transcription factors. Mol. Cell. Biol. 17:1417-1424[Abstract]. |
| 24. |
Jehn, B. M.,
W. Bielke,
W. S. Pear, and B. A. Osborne.
1999.
Cutting edge: protective effects of Notch-1 on TCR-induced apoptosis.
J. Immunol.
162:635-638 |
| 25. |
Jimenez, G.,
Z. Paroush, and D. Ish-Horowicz.
1997.
Groucho acts as a corepressor for a subset of negative regulators, including Hairy and Engrailed.
Genes Dev.
11:3072-3082 |
| 26. | Kamps, M. P., C. Murre, X. H. Sun, and D. Baltimore. 1990. A new homeobox gene contributes the DNA binding domain of the (1;19) translocation protein in pre-B ALL. Cell 60:547-555[CrossRef][Medline]. |
| 27. | Koop, K. E., L. M. MacDonald, and C. G. Lobe. 1996. Transcripts of Grg4, a murine groucho-related gene, are detected in adjacent tissues to other murine neurogenic gene homologues during embryonic development. Mech. Dev. 59:73-87[CrossRef][Medline]. |
| 28. |
Kurosawa, H.,
K. Goi,
T. Inukai,
T. Inaba,
K. S. Chang,
T. Shinjyo,
K. Rakestraw,
C. W. Naeve, and A. T. Look.
1999.
Two candidate downstream target genes for E2A-HLF.
Blood
93:321-332 |
| 29. | Leon, C., and C. G. Lobe. 1997. Grg3, a murine Groucho-related gene, is expressed in the developing nervous system and in mesenchyme-induced epithelial structures. Dev. Dyn. 208:11-24[CrossRef][Medline]. |
| 30. |
Levanon, D.,
R. E. Goldstein,
Y. Bernstein,
H. Tang,
D. Goldenberg,
S. Stifani,
Z. Paroush, and Y. Groner.
1998.
Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors.
Proc. Natl. Acad. Sci. USA
95:11590-11595 |
| 31. |
Look, A. T.
1997.
Oncogenic transcription factors in the human acute leukemias.
Science
278:1059-1064 |
| 32. | Mallo, M., F. Franco del Amo, and T. Gridley. 1993. Cloning and developmental expression of Grg, a mouse gene related to the groucho transcript of the Drosophila Enhancer of split complex. Mech. Dev. 42:67-76[CrossRef][Medline]. |
| 33. | Mallo, M., E. Steingrimsson, N. G. Copeland, N. A. Jenkins, and T. Gridley. 1994. Genomic organization, alternative polyadenylation, and chromosomal localization of Grg, a mouse gene related to the groucho transcript of the Drosophila Enhancer of split complex. Genomics 21:194-201[CrossRef][Medline]. |
| 34. |
Mayo, M. W.,
C. Y. Wang,
P. C. Cogswell,
K. S. Rogers-Graham,
S. W. Lowe,
C. J. Der, and A. S. Baldwin, Jr.
1997.
Requirement of NF- B activation to supperss p53-independent apoptosis induced by oncogenic Ras.
Science
278:1812-1815 |
| 35. |
McLarren, K. W.,
R. Lo,
D. Grbavec,
K. Thirunavukkarasu,
G. Karsenty, and S. Stifani.
2000.
The mammalian basic helix-loop-helix protein HES-1 binds to and modulates the transactivating function of the runt-related factor Cbfa1.
J. Biol. Chem.
275:530-536 |
| 36. | Miyasaka, H., B. K. Choudhury, E. W. Hou, and S. S. Li. 1993. Molecular cloning and expression of mouse and human cDNA encoding AES and ESG proteins with strong similarity to Drosophila enhancer of split groucho protein. Eur. J. Biochem. 216:343-352[Medline]. |
| 37. | Neer, E. J., C. J. Schmidt, R. Nambudripad, and T. F. Smith. 1994. The ancient regulatory-protein family of WD-repeat proteins. Nature 371:297-300[CrossRef][Medline]. |
| 38. | Nourse, J., J. D. Mellentin, N. Galili, J. Wilkinson, E. Stanbridge, S. D. Smith, and M. L. Cleary. 1990. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 60:535-545[CrossRef][Medline]. |
| 39. |
Okuda, T.,
Z. Cai,
S. Yang,
N. Lenny,
C.-J. Lyu,
J. M. A. van Deursen,
H. Harada, and J. R. Downing.
1998.
Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.
Blood
91:3134-3143 |
| 40. | Okuda, T., J. van Deursen, S. W. Hiebert, G. Grosveld, and J. R. Downing. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330[CrossRef][Medline]. |
| 41. | Parkhurst, S. M. 1998. Groucho: making its Marx as a transcriptional co-repressor. Trends Genet. 14:130-132[CrossRef][Medline]. |
| 42. | Paroush, Z., R. L. Finley, Jr., T. Kidd, S. M. Wainwright, P. W. Ingham, R. Brent, and D. Ish-Horowicz. 1994. Groucho is required for Drosophila neurogenesis, segmentation, and sex determination and interacts directly with hairy-related bHLH proteins. Cell 79:805-815[CrossRef][Medline]. |
| 43. |
Pennisi, E.
1998.
How a growth control path takes a wrong turn to cancer.
Science
281:1438-1441 |
| 44. | Price, J. V., E. D. Savenye, D. Lum, and A. Breitkreutz. 1997. Dominant enhancers of Egfr in Drosophila melanogaster: genetic links between the Notch and Egfr signaling pathways. Genetics 147:1139-1153[Abstract]. |
| 45. | Rabbitts, T. H. 1994. Chromosomal translocations in human cancer. Nature 372:143-149[CrossRef][Medline]. |
| 46. | Roose, J., M. Molenaar, J. Peterson, J. Hurenkamp, H. Brantjes, P. Moerer, M. van de Wetering, O. Destree, and H. Clevers. 1998. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395:608-612[CrossRef][Medline]. |
| 47. | Shurtleff, S. A., A. Buijs, F. G. Behm, J. E. Rubnitz, S. C. Raimondi, M. L. Hancock, G. C. Chan, C. H. Pui, G. Grosveld, and J. R. Downing. 1995. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9:1985-1989[Medline]. |
| 48. | Smith, T. E., C. Gaitatzes, K. Saxena, and E. J. Neer. 1999. The WD repeat: a common architecture for diverse functions. Trends Biochem. Sci. 24:181-185[CrossRef][Medline]. |
| 49. | Song, W. J., M. G. Sullivan, R. D. Legare, S. Hutchings, X. Tan, D. Kufrin, J. Ratajczak, I. C. Resende, C. Haworth, R. Hock, M. Loh, C. Felix, D.-C. Roy, L. Busque, D. Kurnit, C. William, A. M. Gewirtz, N. A. Speck, J. H. Bushweller, F. P. Li, K. Gardiner, M. Poncz, J. M. Maris, and D. G. Gilliland. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23:166-175[CrossRef][Medline]. |
| 50. | Stifani, S., C. M. Blaumueller, N. J. Redhead, R. E. Hill, and S. Artavanis-Tsakonas. 1992. Human homologs of a Drosophila Enhancer of split gene product define a novel family of nuclear proteins. Nat. Genet. 2:119-127[CrossRef][Medline]. |
| 51. |
Tolkunova, E. N.,
M. Fujioka,
M. Kobayashi,
D. Deka, and J. B. Jaynes.
1998.
Two distinct types of repression domain in Engrailed: one interacts with the Groucho corepressor and is preferentially active on integrated target genes.
Mol. Cell. Biol.
18:2804-2814 |
| 52. |
Valentine, S. A.,
G. Chen,
T. Shandala,
J. Fernandez,
S. Mische,
R. Saint, and A. J. Courey.
1998.
Dorsal-mediated repression requires the formation of a multiprotein repression complex at the ventral silencer.
Mol. Cell. Biol.
18:6584-6594 |
| 53. | Yan, W., A. Z. Young, V. C. Soares, R. Kelley, R. Benezra, and Y. Zhuang. 1997. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol. Cell. Biol. 17:7317-7327[Abstract]. |
| 54. | Zhuang, Y., P. Soriano, and H. Weintraub. 1994. The helix-loop-helix gene E2A is required for B-cell formation. Cell 79:875-884[CrossRef][Medline]. |
This article has been cited by other articles: